Bayer HealthCare and Ortho-McNeil agree to joint development of BAY 59-7939

By Angela McDaniels

Seattle, Oct. 26 - Bayer HealthCare and Ortho-McNeil Pharmaceutical Inc. said they will jointly develop and market BAY 59-7939 for the prevention of venous thromboembolism.

Ortho-McNeil will share the global development costs and pay an up-front payment and additional milestone payments totaling $290 million.

Ortho-McNeil will then receive exclusive U.S. marketing rights for the cardiology, primary care and hospital specialty markets and pay royalties of up to 30%, the companies said.

Bayer said it will retain an option to co-promote Bay 59-7939 in the hospital and specialty markets and retain sole marketing rights for the compound in countries outside the United States.

In addition, the agreement gives Bayer the rights to co-promote Ortho-McNeil's Elmiron for the relief of bladder pain or discomfort associated with interstitial cystitis in the United States, for which Bayer will receive the full profit.

Bayer HealthCare, a subgroup of Bayer AG, is based in Leverkusen, German, and develops genetically produced medicines, over-the-counter products, diagnostic products and prescription drugs.

Ortho-McNeil is a pharmaceutical company based in Raritan, N.J., and a member of the Johnson & Johnson Family of Companies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.